CXCL9 and neoplasm: In the plasma analytes, only CXCL9, a chemotactic cytokine for T cells in the tumor microenvironment (TME)35, increased between pre- and post-treatment samples (Fig. 3B), but many pro-and anti-inflammatory analytes increased from pre-treatment to pre-cycle 2 (Fig. 3C).